Why is the CSL share price sliding lower on Monday?

Investors should be stoked with CSL's share price drop today.

| More on:
woman testing substance in laboratory dish, csl share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a rough start to the week for the S&P/ASX 200 Index (ASX: XJO) and ASX shares. At the time of writing, the ASX 200 has opened 0.14% lower so far this Monday. But let's talk about the CSL Limited (ASX: CSL) share price. 

If you thought the ASX 200's start to the week was disappointing, wait until you see what's going on with CSL shares. The ASX 200 healthcare stock closed last week at a share price of $270.85. But this morning, CSL opened at $269 a share and is currently going for just $266.65 at the time of writing, down a nasty 1.55% for the day so far.

Before any CSL investors get carried away with wondering what's going wrong with their investment today, it's worth pointing out that there's a good reason for CSL's rather steep drop this Monday. This healthcare share has just traded ex-dividend for its upcoming shareholder payment.

CSL share price stutters as company trades ex-dividend

Last month, we analysed CSL's latest earnings report, covering the full 2023 financial year. It was a well-received earnings report at the time, with the healthcare giant revealing that it had managed to grow revenues by a healthy 31% in constant currency terms to US$13.31 billion.

Net profits after tax before amortisation rose by 20% in constant currency to US$2.86 billion, while reported net profits lifted by 10% to US$2.61 billion.

That enabled CSL to boost its final dividend for 2023 by 9.3% to US$1.29 per share, partially franked at 10%. That's the largest dividend CSL has ever paid out. This payment takes the company's full-year dividends to US$2.36 per share, up 6% from last year.

However, as we warned last week, CSL's ex-dividend date for this supersized shareholder payment is today. This means that anyone buying CSL shares from today onwards is not eligible to receive this latest dividend.

That's why we are seeing such a dramatic fall in the CSL share price this Monday relative to the ASX 200. It usually happens when an ASX share trades ex-dividend, and reflects this inherent loss of value for new investors going forward.

So existing CSL investors have nothing to complain about with their company seeing a share price drop today. It's the best reason to see a company have a red day on the markets.

CSL shareholders can now look forward to receiving their latest dividend next month on 4 October.

Right now, CSL shares have a dividend yield of 1.15%. The CSL share price remains down by 5.5% in 2023 to date, as well as by 10.1% over the past 12 months, as you can see below:

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares up 25% in 2 days as Chemist Warehouse merger looks set

The deal continues to create tailwinds for Sigma shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

500 million reasons why ResMed shares are charging higher today

This growing company has big plans and is forecasting strong growth through to the end of the decade.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on

These companies have developed new drugs to treat vision loss and erectile dysfunction.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Guess which ASX 200 healthcare stock is up 12% on big Chemist Warehouse news

Investors appear to believe this news could be a sign that the deal will go ahead.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Up 630% this year AND profitable! This small ASX healthcare share is glowing

Why has this stock delivered incredible returns this year? Let's find out.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Can the CSL share price push back above $300?

The biotech last traded there on September 9.

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Share Gainers

If you'd invested $6,000 in the ASX 300 stock in January, you'd have $22,551 today!

Shareholders in the ASX 300 stock have the FDA to thank for much of this year’s success.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Guess which small cap ASX stock is rocketing 45% on benchmark agreement

What is getting investors excited on Friday? Let's find out.

Read more »